<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20171015036793N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-02-14</date_registration>
      <primary_sponsor>vice chancellor for research of the Ahvaz Jundishapour University of Medical Sciences</primary_sponsor>
      <public_title>effect of oral and vaginal evening primrose oil on cervical ripening and pregnancy outcomes and compare together</public_title>
      <acronym></acronym>
      <scientific_title>the comparison of oral and vaginal evening primrose oil on cervical ripening in late term pregnancy in nulliparous women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-07-27</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/27413</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The sampling will be done in a sequential non-probabilistic manner, which will be selected as a sample from the start of the study for all pregnant women who have the criteria for entering the study and will continue to reach the final sample size. The assignment of participants to each of the study groups will be done randomly by block method using 6 blocks. In this study, 15 blocks of 6 were designed, in each block, the ratio of the presence of 3 groups in these blocks was 2- 2-2 and is equal, Blinding description: In order to blind people in the oral intervention group, the placebo will be used vaginally, and in the vaginal intervention group, the placebo will be used orally. In order to ensure the reduction of the occurrence of information malpractice and the hypnotic effect of drugs, this double-blind, double-blind trial designed to keep both patients and the treatment staff of the type of treatment intended to be kept unaware.</study_design>
      <phase>N/A</phase>
      <hc_freetext>complications of labor and delivery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: drug group 1, Oral capsule of 1000 mg of primrose oil and one vaginal gelatin capsule beginning admit participant in delivery room(manufacturing by Barrij essence company). Intervention 2: Intervention group: Drug group 2 (vaginal capsule 1000 mg of evening primrose oil and a gelatin capsule orally). Intervention 3: Control group: Placebo (oral capsule 50 mg gelatin).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Khatami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahvaz Jundishapour University of Medical Sciences, Golestan street, Ahvaz</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6135715794</zip>
        <telephone>+98 61 3336 7543</telephone>
        <email>fatemehkhatami71@gmail.com</email>
        <affiliation>Ahvaz Jundishapour University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Shadab Shahali</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahvaz Jundishapour University of Medical Sciences, Golestan street, Ahvaz</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6135715794</zip>
        <telephone>+98 61 3336 7543</telephone>
        <email>shadabshahali@yahoo.com</email>
        <affiliation>School of Nursing and Midwifery, Ahvaz Jundishapour University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>cephalic presentation
alive fetus
with gestational age 40 weeks to42 weeks based on LMP or ultrasound in first trimester
Normal patterns of fetal heart rate
Without uterine contractions
cervical bishop score less than 4 intact membranous
Low-risk pregnancy
( have no known surgical and internal disease or pregnancy complication such as previa, abruption, preeclampsia , no known fetal problems)
Avoiding the enema
Avoiding the Intercourse</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>consumption of laxatives, the use of herbal medicines, chemical or traditional methods for induction of labor</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>O61.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Failed medical induction of labour</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: drug group 1, Oral capsule of 1000 mg of primrose oil and one vaginal gelatin capsule beginning admit participant in delivery room(manufacturing by Barrij essence company)</i_keyword>
      <i_keyword>Intervention group: Drug group 2 (vaginal capsule 1000 mg of evening primrose oil and a gelatin capsule orally)</i_keyword>
      <i_keyword>Control group: Placebo (oral capsule 50 mg gelatin)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Ripening of cervix. Timepoint: during the labor. Method of measurement: bishop score table.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Duration of first, second and third stage of labor. Timepoint: during the labor. Method of measurement: chronometer/examination/check list/observation.</sec_outcome>
      <sec_outcome>Type of delivery. Timepoint: during the labor. Method of measurement: Separation into cesarean section and normal according to how the embryos leave.</sec_outcome>
      <sec_outcome>Infant APGAR score. Timepoint: first and fifth minute after delivery. Method of measurement: apgar table.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>vice chancellor for research of the Ahvaz Jundishapour University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-05-22</approval_date>
        <contact_name>ethics committee of Ahvaz Jundishapour University of Medical Sciences</contact_name>
        <contact_address>Ahvaz Jundishapour University of Medical Sciences, Golestan street; Ahvaz Ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
